Moderna, Inc. - Common Stock (MRNA)

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.

Stocks fell this week as Treasury bond buybacks, oil prices, and Walmart earnings weighed on markets, while Bitcoin rallied; MarketBeat analysts cover Moderna, NVIDIA, Meta, RTX, and more.

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.

Breaking news: Moderna isn't just a "pandemic stock" after all.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 17...

The biotech could be on the verge of setting a new standard of care for skin cancer.

Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission.